Semaglutide
FDA-Approved moleculeCompounded form not FDA-approvedGLP-1 receptor agonist
Medical emergency? If you have a medical emergency, call 911 or go to the nearest emergency room. Do not wait.
- How it works (plain English)
- Mimics the GLP-1 hormone the gut releases after eating. It acts on receptors that influence appetite and the feeling of fullness, and slows how quickly the stomach empties, which can reduce overall food intake.
- Key risks
- Commonly reported: nausea, vomiting, diarrhea, constipation. Boxed warning for thyroid C-cell tumors based on rodent studies; pancreatitis and gallbladder events have been reported.
- Who should not use it
- Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2; known hypersensitivity.
- Drug interactions
- May affect absorption of oral medications due to delayed gastric emptying; additive risk of low blood sugar when combined with insulin or sulfonylureas.
Compounded medications are prepared by licensed US pharmacies on a valid prescription and are not reviewed or approved by the FDA for safety or effectiveness. Treatment is provided only when prescribed by a licensed provider.
This page is general educational information, not medical advice, and is not a complete list of risks. Your prescribing provider will review your full history. Report side effects to your provider; you may also report to the FDA at 1-800-FDA-1088.